Abstract
The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Most low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise patient characterization at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials.
| Original language | English |
|---|---|
| Journal | Klinische Padiatrie |
| Volume | 229 |
| Issue number | 3 |
| Pages (from-to) | 147-167 |
| Number of pages | 21 |
| ISSN | 0300-8630 |
| DOIs | |
| Publication status | Published - 01.05.2017 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of '2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver